IV lignocaine fails to attenuate the cardiovascular response to laryngoscopy and tracheal intubation.
I.v. lignocaine has been used with varying success to attenuate the cardiovascular responses to laryngoscopy and tracheal intubation. We determined the optimal time of administration in 45 ASA I and II Chinese patients premedicated with morphine and hyoscine, and anaesthetized with thiopentone and suxamethonium. Patients were allocated randomly to a control group or three treatment groups to receive lignocaine 1.5 mg kg-1 i.v. 1, 2, or 3 min before laryngoscopy. Analysis of variance for measured and derived cardiovascular variables failed to show any significant difference between any of the groups.
Miller
C D
CD
Grantham Hospital, Aberdeen, Hong Kong.
Warren
S J
SJ
D000328:Adult; D000771:Anesthesia, Intravenous; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D007828:Laryngoscopy / Q000009:adverse effects*; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D013997:Time Factors
D008012:Lidocaine